Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical...
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 Nuvalent to Present Updated Data for ROS1-Selective...
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass., July 11...
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass., May 29, 2024...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 PR Newswire CAMBRIDGE, Mass., May 16, 2024 CAMBRIDGE...
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 Nuvalent Presents New...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...